Pediatric Hemangiomas and Vascular Lesions Overview | MDster You are offline Back online! [ MDster home ](/ "MDster home") Specialities [ Anesthesiology ](https://mdster.com/speciality/anesthesiology) [ Emergency Medicine ](https://mdster.com/speciality/emergency-medicine) [ Family Medicine ](https://mdster.com/speciality/family-medicine) [ Internal Medicine ](https://mdster.com/speciality/internal-medicine) [ Obstetrics & Gynecology ](https://mdster.com/speciality/obstetrics-gynecology) [ Pediatrics ](https://mdster.com/speciality/pediatrics) [ Psychiatry ](https://mdster.com/speciality/psychiatry) [ Features ](https://mdster.com/features) [ Pricing ](https://mdster.com/pricing) [ Blog ](https://mdster.com/blog) Menu Specialities [ Anesthesiology ](https://mdster.com/speciality/anesthesiology) [ Emergency Medicine ](https://mdster.com/speciality/emergency-medicine) [ Family Medicine ](https://mdster.com/speciality/family-medicine) [ Internal Medicine ](https://mdster.com/speciality/internal-medicine) [ Obstetrics & Gynecology ](https://mdster.com/speciality/obstetrics-gynecology) [ Pediatrics ](https://mdster.com/speciality/pediatrics) [ Psychiatry ](https://mdster.com/speciality/psychiatry) [ Features ](https://mdster.com/features) [ Pricing ](https://mdster.com/pricing) [ Blog ](https://mdster.com/blog) [ Login ](https://mdster.com/auth/login) 1. [ Home ](https://mdster.com) 2. [ Blog ](https://mdster.com/blog) 3. [ Medical Education ](https://mdster.com/blog?category=medical-education) 4. Pediatric Hemangiomas and Vascular Lesions: A Practical Overview [ Medical Education ](https://mdster.com/blog?category=medical-education) Pediatric Hemangiomas and Vascular Lesions: A Practical Overview ================================================================== How to separate infantile hemangioma from vascular malformation, predict its course, and know when beta-blockers cannot wait [ MDster Editorial Team ](https://mdster.com/about) · Apr 11, 2026 · 6 min read · 248 [ Reviewed by Dr. Ali Ragab, MBBCH, MSc, MCAI ](https://mdster.com/medical-reviewers/dr-ali-ragab) [Editorial Policy](https://mdster.com/editorial-policy) | [Corrections Policy](https://mdster.com/corrections) [ Board Review ](https://mdster.com/blog?tag=board-review) [ Pediatrics ](https://mdster.com/blog?tag=pediatrics) [ Pediatric Dermatology ](https://mdster.com/blog?tag=pediatric-dermatology) [ Vascular Anomalies ](https://mdster.com/blog?tag=vascular-anomalies) [ Infantile Hemangioma ](https://mdster.com/blog?tag=infantile-hemangioma) ![Pediatric Hemangiomas and Vascular Lesions: A Practical Overview](https://mdster.com/storage/blog/images/pediatric-hemangiomas-and-vascular-lesions-a-practical-overview.jpg) Share this article Share this post On this page 1. [ First split the lesion: tumor or malformation ](#first-split-the-lesion-tumor-or-malformation) 2. [ Infantile hemangioma natural history: the window is early ](#infantile-hemangioma-natural-history-the-window-is-early) 3. [ When to treat: airway and vision are the high-stakes indications ](#when-to-treat-airway-and-vision-are-the-high-stakes-indications) 4. [ The beta-blocker concept ](#the-beta-blocker-concept) 5. [ Clinical Correlations ](#clinical-correlations) 6. [ Key Takeaways ](#key-takeaways) 7. [ Conclusion ](#conclusion) 8. [ Frequently Asked Questions ](#blog-faqs) 9. [ References ](#references-heading) On this page 1. [ First split the lesion: tumor or malformation ](#first-split-the-lesion-tumor-or-malformation) 2. [ Infantile hemangioma natural history: the window is early ](#infantile-hemangioma-natural-history-the-window-is-early) 3. [ When to treat: airway and vision are the high-stakes indications ](#when-to-treat-airway-and-vision-are-the-high-stakes-indications) 4. [ The beta-blocker concept ](#the-beta-blocker-concept) 5. [ Clinical Correlations ](#clinical-correlations) 6. [ Key Takeaways ](#key-takeaways) 7. [ Conclusion ](#conclusion) 8. [ Frequently Asked Questions ](#blog-faqs) 9. [ References ](#references-heading) The common mistake is not missing the diagnosis of infantile hemangioma; it is overcalling every vascular mark a hemangioma and then waiting too long. That is how a 6-week-old with a thickening eyelid lesion drifts toward amblyopia, or an infant with stridor and a beard-distribution plaque turns out to have subglottic disease. High-risk infantile hemangiomas grow earlier than many clinicians expect, so your first job is triage, not reassurance. [\[1\]](#cite-1 "Reference [1]") First split the lesion: tumor or malformation --------------------------------------------- The most useful mental model comes from the ISSVA classification: vascular anomalies are either **vascular tumors** or **vascular malformations**. **Infantile hemangioma (IH)** is the common vascular tumor of infancy. Vascular malformations are structural errors of vasculogenesis—capillary, venous, lymphatic, arteriovenous, or combined lesions. If a mark was fully formed at birth and simply enlarges proportionately with the child, stop calling it IH. [\[2\]](#cite-2 "Reference [2]") FeatureInfantile hemangiomaVascular malformationTimingUsually absent or subtle at birth; appears in first weeksUsually present at birth, though sometimes less obvious earlyGrowthRapid postnatal proliferationGrows commensurately with the childInvolutionRegresses over yearsDoes not involuteTreatment logicObserve or use beta-blocker if high-riskTreat by lesion type; beta-blockers are not standard This distinction is not semantic; it determines prognosis, imaging strategy, and whether a beta-blocker even makes sense. [\[2\]](#cite-2 "Reference [2]") Infantile hemangioma natural history: the window is early --------------------------------------------------------- Classic IH often has a subtle precursor at birth—a pale patch, telangiectatic stain, or bruise-like area—then declares itself over the first weeks. Superficial lesions become bright red; deep lesions may look blue and present later. The fastest growth occurs around **5.5 to 7.5 weeks**, most proliferation is completed by **5 months**, and deep or segmental lesions can grow longer. That is why boards love the timing question: referral for a potentially problematic IH should be **early**, not after it has already distorted anatomy. [\[1\]](#cite-1 "Reference [1]") After proliferation, involution usually starts in later infancy and continues for years. Many lesions are much flatter by **4 to 5 years**, but do not promise normal skin. Residual telangiectasia, fibrofatty tissue, skin laxity, and contour change are common, especially after bulky superficial or mixed lesions. The old line—'leave it alone, it will go away'—is both board-wrong and family-hurting when the site is the eyelid, nasal tip, lip, or breast bud. [\[3\]](#cite-3 "Reference [3]") When to treat: airway and vision are the high-stakes indications ---------------------------------------------------------------- Most IHs can be observed, but treat early if there is actual or imminent harm: **airway compromise, visual risk, ulceration, feeding impairment, pain/bleeding, associated anomalies, or major disfigurement risk**. Periocular IHs can cause deprivation amblyopia, astigmatism, strabismus, and globe displacement. A large facial segmental IH should also push you to think beyond the skin and consider associated structural syndromes. [\[4\]](#cite-4 "Reference [4]") Airway disease is the exam favorite because it is easy to miss. An infant with progressive or biphasic stridor and a cutaneous IH in the **beard distribution** needs urgent airway evaluation; subglottic IH can be life-threatening. Likewise, a rapidly enlarging eyelid lesion at 4 to 8 weeks is an ophthalmologic and dermatologic problem **now**, not next month. AAP guidance emphasizes referral of high-risk IH ideally around **1 month of age**. [\[4\]](#cite-4 "Reference [4]") The beta-blocker concept ------------------------ For problematic IH, **oral propranolol** is first-line systemic therapy. The practical concept is simple: start during proliferation, not after distortion is established. The FDA-approved oral solution is titrated upward over the first 2 weeks, and the pivotal randomized trial showed that **3 mg/kg/day for 6 months** clearly outperformed placebo, with improvement often visible within weeks. For small, thin, superficial lesions, **topical timolol** is a reasonable option. [\[5\]](#cite-5 "Reference [5]") Teach the safety rule every resident forgets to say out loud: give propranolol **during or right after feeds**, and hold it during poor intake, vomiting, or intercurrent illness because **hypoglycemia** is the adverse effect families must understand. Also respect bradycardia, hypotension, and bronchospasm in susceptible infants. Beta-blockers are excellent therapy for the right lesion; they are not magic for every vascular birthmark. [\[6\]](#cite-6 "Reference [6]") > **Clinical Pearl:** A lesion that is **present and fully formed at birth** is usually **not** an infantile hemangioma. A lesion that is **growing fast at 5 to 7 weeks** may still be in the narrow window where treatment prevents permanent damage. [\[7\]](#cite-7 "Reference [7]") Clinical Correlations --------------------- In clinic, reduce the problem to three questions: **Is this really IH? Is function threatened? Is the lesion entering its rapid-growth window?** If the answers are yes, yes, and yes, act early. The biggest pitfall is passive follow-up for a lesion on the eyelid, nose, lip, or beard area that is already telling you it will not behave benignly. [\[4\]](#cite-4 "Reference [4]") Key Takeaways ------------- - **IH is a vascular tumor; vascular malformations are structural lesions that are usually present at birth, grow commensurately, and do not involute.** [\[2\]](#cite-2 "Reference [2]") - **IH grows fastest in early infancy, often before 2 months, and most proliferation is done by 5 months.** [\[1\]](#cite-1 "Reference [1]") - **Treat early when airway, vision, feeding, ulceration, pain, or major disfigurement risk is present.** [\[4\]](#cite-4 "Reference [4]") - **Beard-distribution IH plus stridor means think subglottic involvement; periocular IH means think amblyopia and astigmatism.** [\[4\]](#cite-4 "Reference [4]") - **Oral propranolol is first-line for problematic IH; give it with feeds and hold it during poor intake or illness to reduce hypoglycemia risk.** [\[5\]](#cite-5 "Reference [5]") Conclusion ---------- When you see a vascular birthmark in an infant, do not ask only what it is. Ask what it will do in the next 4 weeks. That shift in thinking is how you catch the hemangioma that threatens airway, vision, or anatomy before the window closes. [\[1\]](#cite-1 "Reference [1]") Frequently Asked Questions ---------------------------- ### How do I distinguish an infantile hemangioma from a port-wine stain at the bedside? A port-wine stain is a **capillary malformation**: it is typically present at birth and grows with the child. An **infantile hemangioma** is often absent or subtle at birth, then proliferates during the first weeks of life. [\[2\]](#cite-2 "Reference [2]") ### Does every infantile hemangioma need propranolol? No. Many IHs are observed. Treat when there is risk to airway, vision, feeding, skin integrity, or long-term disfigurement, or when associated anomalies are a concern. [\[4\]](#cite-4 "Reference [4]") ### When should eyelid or beard-distribution lesions be referred urgently? Urgently and early—ideally by about **1 month of age** for high-risk lesions. Periocular IH threatens vision, and beard-distribution IH with stridor raises concern for subglottic involvement. [\[4\]](#cite-4 "Reference [4]") ### Do hemangiomas always leave normal skin after involution? No. Many flatten substantially, but residual telangiectasia, fibrofatty tissue, lax skin, or contour change are common, especially after bulky lesions. [\[3\]](#cite-3 "Reference [3]") References (8) ------------------ 1. 1. [ Tollefson MM, Frieden IJ. Early growth of infantile hemangiomas: what parents' photographs tell us. Pediatrics. 2012. ](https://pubmed.ncbi.nlm.nih.gov/22826568/) [↩](#cite-ref-1-1 "Back to text") 2. 2. [ International Society for the Study of Vascular Anomalies. ISSVA Classification for Vascular Anomalies. 2025. ](https://www.issva.org/education/classification) [↩](#cite-ref-2-1 "Back to text") 3. 3. [ www.healthychildren.org/Spanish/ages-stages/baby/bathing-skin-care/Paginas/Infantile-Hemangiomas-Baby-Birthmarks.aspx ](https://www.healthychildren.org/Spanish/ages-stages/baby/bathing-skin-care/Paginas/Infantile-Hemangiomas-Baby-Birthmarks.aspx) [↩](#cite-ref-3-1 "Back to text") 4. 4. [ publications.aap.org/pediatrics/article/136/4/e1060/73846/Diagnosis-and-Management-of-Infantile-Hemangioma ](https://publications.aap.org/pediatrics/article/136/4/e1060/73846/Diagnosis-and-Management-of-Infantile-Hemangioma) [↩](#cite-ref-4-1 "Back to text") 5. 5. [ Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015. ](https://pubmed.ncbi.nlm.nih.gov/25693013/) [↩](#cite-ref-5-1 "Back to text") 6. 6. [ DailyMed. HEMANGEOL (propranolol hydrochloride oral solution) prescribing information. ](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6f9dd2a-632b-87eb-70f0-b2064d7ed48a) [↩](#cite-ref-6-1 "Back to text") 7. 7. [ pubmed.ncbi.nlm.nih.gov/7063565 ](https://pubmed.ncbi.nlm.nih.gov/7063565/) [↩](#cite-ref-7-1 "Back to text") 8. 8. [ Krowchuk DP, Frieden IJ, Mancini AJ, et al. Clinical Practice Guideline for the Management of Infantile Hemangiomas. Pediatrics. 2019. ](https://doi.org/10.1542/peds.2018-3475) Study pathway Practice Pediatrics the way boards test ----------------------------------------- - Age‑specific differentials and management - Growth, development, and immunizations - Target weak areas with smart review Free 5-day trial No credit card required. [ Start practicing ](https://mdster.com/user/dashboard) [ Explore Pediatrics ](https://mdster.com/speciality/pediatrics) [ View pricing ](https://mdster.com/pricing) [ Explore features ](https://mdster.com/features) No credit card required. Full access to all features. No commitment. Cancel anytime. Explore topics: [ # Board Review ](https://mdster.com/blog?tag=board-review) [ # Pediatrics ](https://mdster.com/blog?tag=pediatrics) [ # Pediatric Dermatology ](https://mdster.com/blog?tag=pediatric-dermatology) [ # Vascular Anomalies ](https://mdster.com/blog?tag=vascular-anomalies) [ # Infantile Hemangioma ](https://mdster.com/blog?tag=infantile-hemangioma) [ Back to all posts ](https://mdster.com/blog) Discussion () ----------------- Join the discussion [ Log in ](https://mdster.com/auth/login) or [ Sign up ](https://mdster.com/auth/register) No comments yet Be the first to share your thoughts! ![]() More in Medical Education ------------------------- [ See all ](https://mdster.com/blog?category=medical-education) [### Medical Comorbidities and Medication Review in OB History 5 min read May 26, 2026 ](https://mdster.com/blog/medical-comorbidities-and-medication-review-in-ob-history) [### Type 2 Diabetes Pharmacotherapy: ASCVD, HF, CKD First 5 min read May 25, 2026 ](https://mdster.com/blog/type-2-diabetes-pharmacotherapy-ascvd-hf-ckd-first) [### Acute Severe Colitis and Toxic Megacolon in IBD: Rescue and Surgery 5 min read May 24, 2026 ](https://mdster.com/blog/acute-severe-colitis-and-toxic-megacolon-in-ibd-rescue-and-surgery) Related Posts ------------- [ ![American Board of Pediatrics (General Pediatrics Certifying Examination): Practical Study Plan](https://mdster.com/storage/blog/images/american-board-of-pediatrics-general-pediatrics-certifying-examination-practical-study-pla.jpg) Study Tips ### American Board of Pediatrics (General Pediatrics Certifying Examination): Practical Study Plan Prepare for the ABP General Pediatrics Certifying Examination with a practical 12-week schedule, blueprint-based priorities, and exam-day tactics. 5 min read 0 comments ](https://mdster.com/blog/american-board-of-pediatrics-general-pediatrics-certifying-examination-practical-study-pla) [ ![Medical Comorbidities and Medication Review in OB History](https://mdster.com/storage/blog/images/medical-comorbidities-and-medication-review-in-ob-history.jpg) Medical Education ### Medical Comorbidities and Medication Review in OB History Learn a structured OB history approach to comorbidities, medication review, anesthesia risk, allergies, and teratogen exposure screening. 5 min read 0 comments ](https://mdster.com/blog/medical-comorbidities-and-medication-review-in-ob-history) [ ![Liver Transplant Anesthesia: Reperfusion Collapse Case](https://mdster.com/storage/blog/images/liver-transplant-anesthesia-reperfusion-collapse-case.jpg) Case Discussion ### Liver Transplant Anesthesia: Reperfusion Collapse Case A board-focused liver transplant anesthesia case covering postreperfusion syndrome, hyperkalemia, citrate toxicity, fibrinolysis, and ICU handoff priorities. 6 min read 0 comments ](https://mdster.com/blog/liver-transplant-anesthesia-reperfusion-collapse-case) [ ![Type 2 Diabetes Pharmacotherapy: ASCVD, HF, CKD First](https://mdster.com/storage/blog/images/type-2-diabetes-pharmacotherapy-ascvd-hf-ckd-first.jpg) Medical Education ### Type 2 Diabetes Pharmacotherapy: ASCVD, HF, CKD First Learn a high-yield, board-focused approach to type 2 diabetes pharmacotherapy using ASCVD, HF, CKD, adverse effects, and insulin triggers. 5 min read 0 comments ](https://mdster.com/blog/type-2-diabetes-pharmacotherapy-ascvd-hf-ckd-first) [ ![Acute Severe Colitis and Toxic Megacolon in IBD: Rescue and Surgery](https://mdster.com/storage/blog/images/acute-severe-colitis-and-toxic-megacolon-in-ibd-rescue-and-surgery.jpg) Medical Education ### Acute Severe Colitis and Toxic Megacolon in IBD: Rescue and Surgery Recognize acute severe colitis and toxic megacolon early, use IV steroids correctly, and know when rescue therapy or colectomy is the safest move. 5 min read 0 comments ](https://mdster.com/blog/acute-severe-colitis-and-toxic-megacolon-in-ibd-rescue-and-surgery) [ ![Agitated Schizophrenia, Meth Use, ACT, and LAI Planning](https://mdster.com/storage/blog/images/agitated-schizophrenia-meth-use-act-and-lai-planning.jpg) Case Discussion ### Agitated Schizophrenia, Meth Use, ACT, and LAI Planning A high-yield psychiatry case on acute agitation, stimulant-associated psychosis, ACT teams, LAI antipsychotics, and capacity around housing refusal. 5 min read 0 comments ](https://mdster.com/blog/agitated-schizophrenia-meth-use-act-and-lai-planning) [ MDster home ](/ "MDster home") Master your medical exams with evidence-based learning. [ GET IT ON Google Play ](https://play.google.com/store/apps/details?id=com.mdster.app) Platform - [Home](https://mdster.com) - [Features](https://mdster.com/features) - [Pricing](https://mdster.com/pricing) - [About](https://mdster.com/about) Resources - [Blog](https://mdster.com/blog) - [Dashboard](https://mdster.com/user/dashboard) Support - [Contact](https://mdster.com/contact) - [Legal & Policies](https://mdster.com/legal) - [Medical Reviewers](https://mdster.com/medical-reviewers) © 2026 MDster [ ](https://play.google.com/store/apps/details?id=com.mdster.app) [Terms](https://mdster.com/terms) [Privacy](https://mdster.com/privacy) [Editorial](https://mdster.com/editorial-policy) reCAPTCHA Protected by reCAPTCHA. Google [Privacy Policy](https://policies.google.com/privacy) and [Terms of Service](https://policies.google.com/terms) apply. Cookie Consent -------------- We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. [ Terms of Use ](https://mdster.com/terms) & [ Privacy Policy ](https://mdster.com/privacy) Accept